Patents by Inventor Dinah Parums

Dinah Parums has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050148585
    Abstract: This invention relates to the use of cyclic guanosine 3?, 5?-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.
    Type: Application
    Filed: August 26, 2004
    Publication date: July 7, 2005
    Inventors: Michael Davies, Jonathan Huggins, Dinah Parums
  • Publication number: 20050106638
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Application
    Filed: August 30, 2004
    Publication date: May 19, 2005
    Applicant: Pfizer Inc.
    Inventors: Dinah Parums, Stephen Phillips, John Ridden
  • Patent number: 6794192
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: September 21, 2004
    Assignee: Pfizer Inc.
    Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
  • Publication number: 20030040041
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Application
    Filed: June 28, 2001
    Publication date: February 27, 2003
    Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
  • Publication number: 20020065286
    Abstract: This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.
    Type: Application
    Filed: August 10, 2001
    Publication date: May 30, 2002
    Inventors: Michael John Davies, Jonathan Paul Huggins, Dinah Parums